Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032285 (pneumonia)
 54,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 3-year mortality and morbidity survey was conducted in a research foxhound breeding colony. Its purpose was to identify specific problem areas for further study and rectification. Three-hundred and thirty-nine litters (2,872 puppies) were whelped. Seventeen percent (17.4%) of the puppies died before weaning and 4.0% died between weaning and 30 weeks of age. Major puppy losses (55.6% of the total mortality) occurred during the 1st week after birth. The majority of deaths during this period was attributable to stillbirth, immaturity or runting, trauma and congenital abnormalities. The predominant causes of death thereafter were pneumonia, malnutrition, and gastrointestinal disease. The most frequent causes of morbidity among puppies were respiratory disease, anorexia and dehydration, skin disorders, and gastrointestinal disease. These entities were most commonly observed during the 2 weeks before and after weaning at 6 weeks of age. Clinical disease problems among breeding stock were few and were easily resolved. Fighting and infections of the skin and ear canals constituted 75.5% of the cases observed.
 ...
PMID:Morbidity and mortality in a closed foxhound breeding colony. 55 6

Detection of cytomegalovirus (CMV) antigenemia was compared with shell vial centrifugation cultures for rapid detection of CMV infection. In a prospective study, 59 CMV seropositive patients were monitored weekly during the first 100 days after allogeneic marrow transplantation for virus excretion from urine, throat, and blood and for antigenemia by direct staining of peripheral leukocytes using an antibody pool directed against pp 65. Antigenemia was present in 21 of 22 patients with culture-proven CMV infection and in 3 of 37 without culture-proven CMV infection (sensitivity 95%, specificity 91%). The median time of onset of antigenemia and shell vial cultures was day 47 and 55 after transplant, respectively (P = .0006). Among patients who developed CMV disease without preceding cultures, antigenemia was detected in all patients with CMV pneumonia (N = 6) and in two of three patients with gastrointestinal disease by a median of 10 and 7 days, respectively, before the onset of disease (P = .0002). Levels of antigenemia were significantly higher in patients with disease or viremia than in patients with excretion from urine or throat (P less than .05). Whether the antigenemia assay is more sensitive than rapid culture methods to focus antiviral prophylaxis in marrow transplant patients must be determined in controlled studies.
 ...
PMID:Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. 132 14

Cytomegalovirus (CMV), a major opportunistic viral pathogen frequently causing disease in immunocompromised patients such as organ transplant recipients and people with AIDS, may present as pneumonitis, gastrointestinal disease, or encephalitis. Its most common manifestation in patients with AIDS is retinitis which, if left untreated, invariably progresses to extensive retinal necrosis and ultimately to blindness. Ganciclovir sodium, currently the only licensed antiviral agent for the treatment of CMV retinitis, effectively controls this infection in a majority of AIDS patients, but significant granulocytopenia or thrombocytopenia related to ganciclovir therapy often limit its clinical application. Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir. Foscarnet sodium, a pyrophosphate analog active against both cytomegalovirus and the human immunodeficiency virus type 1 (HIV), may be an effective alternative to ganciclovir in the management of CMV retinitis. Trials with intravenous foscarnet in CMV retinitis have reported favorable results using initial daily doses of 180-230 mg/kg/d given as intermittent infusions every eight hours, followed by maintenance regimens of 60-90 mg/kg/d given as single daily one- or two-hour infusions. Foscarnet therapy may result in renal impairment, and indefinite intravenous maintenance therapy may be required to prevent recurrence of CMV infection. Despite these drawbacks, foscarnet's lack of major myelosuppressive toxicity, and its activity in suppressing HIV replication, make this a potentially safe and effective alternative agent for the management of CMV infection, especially in AIDS patients.
 ...
PMID:Foscarnet sodium. 184 59

Cytomegalovirus (CMV) infection is the most important single infectious complication of organ transplantation, affecting more than 70% of transplant recipients. Its emergence as a major pathogen has coincided with the use of cytotoxic therapy. Manifestations of serious CMV disease include: pneumonia, hepatitis, gastrointestinal disease, leukopenia and chorioretinitis. CMV is associated with superinfection with opportunistic organisms, graft failure and increased mortality. Serious infection most frequently occurs with primary CMV infection in which latently infected cells from CMV-positive donors are given to seronegative recipients. Pediatric patients who have a lower pre-transplant rate of CMV seropositivity are at particularly high risk of developing serious CMV disease. Preventative efforts range from the ideal but impractical use of only CMV-negative donors (organ and blood products), to the use of CMV hyperimmune globulin and antiviral chemotherapy. Data support the use of prophylactic hyperimmune globulin and preliminary information supports the use of prophylactic high-dose acyclovir in renal transplant patients. Prophylactic gancyclovir alone or with hyperimmune globulin and pre-transplant vaccination with live-attenuated Towne strain CMV vaccine remain investigational.
 ...
PMID:Prevention of cytomegalovirus infection in the pediatric renal transplant recipient. 185 Oct 31

Though the rubella vaccination programme for adolescent girls was introduced in Japan in 1977, rubella epidemics have occurred repeatedly. Also in Sasebo, Japan in 1987, we experienced various complications as follows: encephalitis (five cases), meningitis (three), thrombocytopenic purpura (four), vascular purpura (four), hemolytic anemia (two), pneumonia (eight), protein-losing gastroenteropathy (one), multiple organ disorder with encephalitis, purpura, myocarditis, hepatic and renal dysfunction (one), and congenital rubella syndrome (CRS: three). Disorders ranging over multiple organs seem to occur in acquired as well as congenital rubella infection. The incidence of encephalitis was estimated to be 1:1600 cases of rubella and two of five cases were apparently serious. Though the strategy for preventing rubella has been directed only against CRS, we should note the various and severe complications with acquired rubella infection, and should adopt two-stepped protection: vaccination of young children of both sexes and of adolescent girls.
 ...
PMID:A rubella epidemic in Sasebo, Japan in 1987, with various complications. 210 90

Feline leukemia virus status and antibody titer to feline oncornavirus-associated cell membrane antigen (FOCMA) were determined on plasma from 183 outpatient cats and 61 cats from 2 closed, FeLV-positive, multiple-cat households. Cats with FOCMA antibody titer had a significantly (P less than 0.02) higher prevalence of history of disease than did cats without FOCMA antibody. Diseases included upper respiratory tract infections, abscesses, ear infections, lower urinary tract infections, gastrointestinal disease, pneumonia, uterine infection, lymphadenopathy, fever of unknown origin, and bacterial infections. The FOCMA antibody titer was determined by use of an indirect fluorescent antibody test; titer greater than or equal to 1:16 was considered to be positive results. Lower mean FOCMA antibody titer was observed in young cats with history of disease (P less than 0.05) than in young cats without history of disease or in older cats with or without history of disease. Prevalence of FOCMA antibody titer was identical (38%) in young and adult cats, indicating cats likely were exposed to FeLV as kittens because a higher prevalence of FOCMA antibody titer in older cats would otherwise be expected.
 ...
PMID:Prevalence of disease in nonviremic cats previously exposed to feline leukemia virus. 215 93

We performed a retrospective study on 112 patients with AIDS-related pneumonias who underwent bronchoscopy and in whom Pneumocystis carinii pneumonia (PCP) and/or cytomegalovirus (CMV) were identified in bronchoalveolar fluid (BAL). CMV was identified by detection of early antigen fluorescent foci (DEAFF) testing in cell cultures of BAL fluid. The short- and long-term survival of all patients was similar regardless of whether PCP, CMV or both were detected at bronchoscopy. Ten out of 14 patients with CMV alone and 13 out of 26 with both CMV and PCP were treated with anti-CMV therapy, but the short- and long-term mortality was similar to that in patients who had no specific antiviral therapy. Extrapulmonary recurrence of CMV (retinitis or gastrointestinal disease) occurred in 22% of patients with evidence of CMV in BAL compared with 16% of those with PCP alone, but this difference was not statistically significant and this recurrence rate was independent of anti-CMV therapy. Detection of CMV shedding from more than one site (BAL, urine, throat or blood) was associated with a worse prognosis at 3 months than in patients in whom CMV was detected in BAL alone. It does not appear that finding CMV shedding is a guide to the cause of pneumonia or an indication for treatment in AIDS patients.
 ...
PMID:The significance of the detection of cytomegalovirus in the bronchoalveolar lavage fluid in AIDS patients with pneumonia. 216 73

Cytomegalovirus (CMV) viremia and excretion from the oropharynx and urine were examined for their utility in predicting the development of CMV disease, including pneumonia and gastrointestinal disease, among 617 marrow allograft recipients. CMV viremia had a 60% and excretion from oropharynx or urine or viremia a 44% positive predictive value for the development of CMV disease. Viremia or excretion preceded disease onset by a median of 15 days among those in whom excretion occurred first. In stepwise time-dependent proportional hazards regression analyses, CMV viremia and positive serology before transplant were predictive for both CMV pneumonia and gastrointestinal disease. Oropharyngeal excretion was independently predictive for gastrointestinal disease but not pneumonia. Urinary excretion was not independently predictive. Acute graft-versus-host disease was predictive for pneumonia but not gastrointestinal disease. Thus use of CMV excretion, particularly viremia, as a marker to determine the initiation of antiviral chemotherapy could be effective in preventing progression of infection to serious disease. However, with standard virologic techniques this strategy would not be effective in patients (32% in this study) without CMV excretion detected before the onset of pneumonia or gastrointestinal disease.
 ...
PMID:Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. 216 10

Treatment of cytomegalovirus (CMV) disease met with limited success until the development of ganciclovir. Favorable clinical responses to ganciclovir have been reported in approximately 80% of immunocompromised patients with CMV retinitis or gastrointestinal disease. CMV pneumonia is more difficult to treat, with therapy benefiting 10%-72% of patients. Ganciclovir must be given parenterally; the dose-limiting adverse event is neutropenia. Patients with AIDS frequently experience relapse and require maintenance therapy. Foscarnet is an attractive anti-CMV drug but must be given parenterally and is completely dependent on renal clearance for elimination. Prevention of CMV disease with antiviral drugs may be possible. Five weeks of intravenous acyclovir (500 mg/m2 three times a day) significantly reduced the risk of CMV infection and disease in seropositive allogeneic bone marrow transplant recipients. The prophylactic benefit of acyclovir has recently been confirmed and extended by a placebo-controlled trial in renal allograft recipients at the University of Minnesota. A 12-week course of high doses of oral acyclovir (3,200 mg/d) was safe and significantly reduced the incidence of CMV infection and disease.
 ...
PMID:Management of cytomegalovirus disease with antiviral drugs. 217 14

The acquired immunodeficiency syndrome (AIDS) is complex in nature with one major aetiological factor but with numerous other agents exploiting the immune incompetence. Cytomegaloviruses (CMV) form a little-defined group of viruses which naturally persist in man and respond readily to the relaxation in immune surveillance. A role for CMV and other herpesviruses in potentiating the underlying infection with human immune deficiency virus (HIV) cannot be totally excluded but CMV is well established as a major opportunist in AIDS. They are considered responsible for a range of diseases in AIDS patients including retinitis, gastrointestinal disease, pneumonitis and, less frequently, encephalitis. The pyrophosphate analogue foscarnet (phosphonoformate) and the deoxyguanosine analogue ganciclovir have both been used to treat CMV infections in AIDS patients. Results of uncontrolled studies have indicated efficacy with both drugs but the work with ganciclovir is particularly encouraging. This communication provides a review of CMV infections in AIDS patients with special reference to the experiences to-date in the use of ganciclovir and foscarnet.
 ...
PMID:Cytomegalovirus and the acquired immunodeficiency syndrome. 254 Nov 27


1 2 3 4 5 Next >>